To include your compound in the COVID-19 Resource Center, submit it here.

Quark's QPI-1002 meets Phase II kidney injury endpoint

Quark Pharmaceuticals Inc. (Fremont, Calif.) reported data from a Phase II trial in 341 patients at high risk of acute kidney injury (AKI) following cardiac surgery showing that a

Read the full 298 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE